替吉奥联合奥沙利铂治疗晚期胃癌合并肝转移的临床疗效及安全性

S-1 combined with oxaliplatin in the treatment of clinical efficacy and safety study of advanced gastric cancer with liver metastasis

目的:探讨替吉奥联合奥沙利铂治疗晚期胃癌合并肝转移的临床疗效及安全性。方法:选取2015年1月至2016年12月我院收治的晚期胃癌合并肝转移患者90例,随机分为两组,对照组替吉奥治疗,研究组替吉奥联合奥沙利铂治疗,对比两组患者临床疗效以及安全性,同时对比两组患者治疗前后的基质金属蛋白酶-9(MMP-9)以及血管内皮生长因子(VEGF)水平。结果:临床疗效对比方面,研究组患者治疗有效率优于对照组(P<0.05);安全性对比方面,研究组患者不良反应发生情况低于对照组(P<0.05);治疗前两组患者的MMP-9以及VEGF无明显区别(P>0.05),治疗后均得到一定改善,研究组优于对照组(P<0.05)。结论:晚期胃癌合并肝转移患者联合应用替吉奥以及奥沙利铂,有利于提高临床治疗效果,降低不良反应发生风险,改善MMP-9以及VEGF指标,应当推广应用。

Objective：To investigate the effect of S-1 combined with oxaliplatin in treatment of advanced gastric cancer clinical efficacy and safety of combined hepatic metastasis.Methods：90 patients from January 2015 to December 2016 year in our hospital of advanced gastric cancer with liver metastasis,were randomly divided into two groups,the control group used S-1 for study group,combined with oxaliplatin in the treatment,compared two groups of patients with clinical curative effect and safety,and compared the two groups before and after treatment in patients with MMP-9 and vascular endothelial growth factor level （VEGF）.Results：The clinical curative effect of patients in the study group,the effective rate of treatment was significantly better than the control group （P〈 0.05）.Safety of patients in the study group,the incidence of adverse reactions was significantly lower than the control group （P〈0.05）,the two groups of patients with MMP-9 and VEGF had no significant difference before treatment （P〉0.05）,all get some improvement after treatment,the study group was significantly better than the control group （P〈0.05）.Conclusion：The combined application of oxaliplatin combined with liver and patients with S-1 in advanced gastric cancer metastasis,improve the clinical treatment effect,reduce the risk of adverse reactions,improve MMP-9 and VEGF indicators should be applied.